keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/28319497/vertebral-hemangioma-mimicking-bone-metastasis-in-68ga-psma-ligand-pet-ct
#1
Carlos Artigas, François-Xavier Otte, Marc Lemort, Roland van Velthoven, Patrick Flamen
Ga-PSMA PET/CT was performed in a 68-year-old man to evaluate recurrent prostate cancer due to elevated serum prostate-specific antigen level. Images showed a focal uptake in the prostatic gland, suggesting local relapse, and an intense uptake in the 12th thoracic vertebra, with no morphological abnormalities in CT slices. In order to confirm extraprostatic disease and before radiotherapy planning, a full-spine MRI was performed, resulting with the morphological pattern of a vertebral hemangioma. Hystological analysis confirmed the local relapse in the prostate...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28319496/the-utility-of-68ga-psma-pet-ct-in-poorly-differentiated-metastatic-prostate-cancer
#2
Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Burcu Ucar, Yesim Saglican
We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. Ga-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28317152/-68-ga-psma-pet-for-radiation-treatment-planning-in-prostate-cancer-recurrences-after-surgery-individualized-medicine-or-new-standard-in-salvage-treatment
#3
Gregor Habl, Katharina Sauter, Kilian Schiller, Sabrina Dewes, Tobias Maurer, Matthias Eiber, Stephanie E Combs
BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP± prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department...
March 20, 2017: Prostate
https://www.readbyqxmd.com/read/28314971/-when-is-surgical-treatment-indicated-in-metastatic-prostate-cancer-and-what-is-the-scientific-rationale
#4
A Kretschmer, A Herlemann, C G Stief, C Gratzke
BACKGROUND: Recent improvements in imaging diagnostics has led to a rising incidence of oligometastatic prostate cancer and, most notably, an increasing incidence of nodal-only biochemical recurrences. In this clinical setting, systemic therapy is still the treatment of choice. However, there is increasing evidence for surgical approaches in this challenging clinical setting. AIM OF THE STUDY: In this comprehensive review article, current evidence regarding surgical approaches of primary nodal metastases, nodal-only biochemical recurrence following radical prostatectomy, and osseous metastatic prostate cancer will be discussed...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314292/-68-ga-psma-ligand-pet-ct-based-radiotherapy-for-lymph-node-relapse-of-prostate-cancer-after-primary-therapy-delays-initiation-of-systemic-therapy
#5
Christoph Henkenberens, Christoph A VON Klot, Tobias L Ross, Frank M Bengel, Hans-Jürgen Wester, Hüper Katja, Hans Christiansen, Thorsten Derlin
AIM: To evaluate (68)Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy. PATIENTS AND METHODS: Twenty-three patients received radiotherapy for PSMA ligand-positive lymph node metastases. RESULTS: The median follow-up time was 12.4 (range=6.0-28.5) months. The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303694/lutetium-177-psma-radionuclide-therapy-for-men-with-prostate-cancer-a-review-of-the-current-literature-and-discussion-of-practical-aspects-of-therapy
#6
REVIEW
Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee
Prostate-specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high-binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides...
March 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28302763/phase-2-study-of-99m-tc-trofolastat-spect-ct-to-identify-and-localize-prostate-cancer-in-intermediate-and-high-risk-patients-undergoing-radical-prostatectomy-and-extended-pelvic-lymph-node-dissection
#7
Karolien E Goffin, Steven Joniau, Peter Tenke, Kevin Slawin, Eric A Klein, Nancy Stambler, Thomas Strack, John Babich, Thomas Armor, Vivien Wong
Rationale:(99m)Tc-trofolastat ((99m)Tc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen (PSMA), shows high potential to detect prostate cancer (PCa) non-invasively using single-photon-emission-computed-tomography (SPECT). We therefore wanted to assess the performance of (99m)Tc-trofolastat SPECT/CT in a phase 2 multi-center, multi-reader prospective study in patients with intermediate- and high-grade PCa, prior to radical prostatectomy and extended pelvic lymph node dissection, with histopathology as gold standard...
March 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28301262/-213-bi-labeled-prostate-specific-membrane-antigen-targeting-agents-induce-dna-double-strand-breaks-in-prostate-cancer-xenografts
#8
Julie Nonnekens, Kristell L S Chatalic, Janneke D M Molkenboer-Kuenen, Cecile E M T Beerens, Frank Bruchertseifer, Alfred Morgenstern, Joke Veldhoven-Zweistra, Margret Schottelius, Hans-Jürgen Wester, Dik C van Gent, Wytske M van Weerden, Otto C Boerman, Marion de Jong, Sandra Heskamp
BACKGROUND: Up to now, prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy mainly focused on β-emitting radionuclides. Herein, two new (213)Bi-labeled agents for PSMA-targeted α therapy of prostate cancer (PCa) are reported. METHODS: The biodistribution of (213)Bi-labeled small-molecule inhibitor PSMA I&T and nanobody JVZ-008 was evaluated in mice bearing PSMA-positive LNCaP xenografts. DNA damage response was followed using LNCaP cells and LNCaP xenografts...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28295408/circulating-tumor-cells-as-a-marker-for-progression-free-survival-in-metastatic-castration-na%C3%A3-ve-prostate-cancer
#9
Andreas Josefsson, Anna Linder, Despina Flondell Site, Giacomo Canesin, Anna Stiehm, Aseem Anand, Anders Bjartell, Jan-Erik Damber, Karin Welén
BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study...
March 10, 2017: Prostate
https://www.readbyqxmd.com/read/28292957/psma-redirects-cell-survival-signaling-from-the-mapk-to-the-pi3k-akt-pathways-to-promote-the-progression-of-prostate-cancer
#10
Leslie Ann Caromile, Kristina Dortche, M Mamunur Rahman, Christina L Grant, Christopher Stoddard, Fernando A Ferrer, Linda H Shapiro
Increased abundance of the prostate-specific membrane antigen (PSMA) on prostate epithelium is a hallmark of advanced metastatic prostate cancer (PCa) and correlates negatively with prognosis. However, direct evidence that PSMA functionally contributes to PCa progression remains elusive. We generated mice bearing PSMA-positive or PSMA-negative PCa by crossing PSMA-deficient mice with transgenic PCa (TRAMP) models, enabling direct assessment of PCa incidence and progression in the presence or absence of PSMA...
March 14, 2017: Science Signaling
https://www.readbyqxmd.com/read/28285160/ethanol-dispersed-and-antibody-conjugated-polymer-nanofibers-for-the-selective-capture-and-3-dimensional-culture-of-epcam-positive-cells
#11
Junghyo Yoon, Hee-Sook Yoon, Yoojin Shin, Sanghyun Kim, Youngjun Ju, Jungbae Kim, Seok Chung
Electrospun and ethanol-dispersed polystyrene-poly(styrene-co-maleic anhydride) (PS-PSMA) nanofibers (NFs) were used as a platform for the selective capture and three-dimensional culture of EpCAM-positive cells in cell culture medium and whole blood. The NFs were treated with streptavidin to facilitate bond formation between the amino groups of streptavidin and the maleic anhydride groups of the NFs. A biotinylated anti-EpCAM monoclonal antibody (mAb) was attached to the streptavidin-conjugated NFs via the selective binding of streptavidin and biotin...
March 8, 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/28283702/-68-ga-psma-pet-ct-joint-eanm-and-snmmi-procedure-guideline-for-prostate-cancer-imaging-version-1-0
#12
Wolfgang P Fendler, Matthias Eiber, Mohsen Beheshti, Jamshed Bomanji, Francesco Ceci, Steven Cho, Frederik Giesel, Uwe Haberkorn, Thomas A Hope, Klaus Kopka, Bernd J Krause, Felix M Mottaghy, Heiko Schöder, John Sunderland, Simon Wan, Hans-Jürgen Wester, Stefano Fanti, Ken Herrmann
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of (68)Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of (68)Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
March 10, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28280856/comparison-of-standard-and-delayed-imaging-to-improve-the-detection-rate-of-68-ga-psma-i-t-pet-ct-in-patients-with-biochemical-recurrence-or-prostate-specific-antigen-persistence-after-primary-therapy-for-prostate-cancer
#13
Sebastian Schmuck, Stefan Nordlohne, Christoph-A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
PURPOSE: The aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate cancer, using the prostate-specific membrane antigen (PSMA) ligand [(68)Ga]PSMA I&T. METHODS: 240 patients who underwent a [(68)Ga]PSMA I&T PET/CT in the context of biochemical relapse of prostate cancer were included in this retrospective analysis. Imaging consisted of a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p...
March 9, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28280855/repeated-psma-targeting-radioligand-therapy-of-metastatic-prostate-cancer-with-131-i-mip-1095
#14
Ali Afshar-Oromieh, Uwe Haberkorn, Christian Zechmann, Thomas Armor, Walter Mier, Fabian Spohn, Nils Debus, Tim Holland-Letz, John Babich, Clemens Kratochwil
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. METHODS: Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with (131)I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy...
March 9, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28273651/comparative-preclinical-evaluation-of-68-ga-nodaga-and-68-ga-hbed-cc-conjugated-procainamide-in-melanoma-imaging
#15
György Trencsényi, Noémi Dénes, Gábor Nagy, Adrienn Kis, András Vida, Flóra Farkas, Judit P Szabó, Tünde Kovács, Ervin Berényi, Ildikó Garai, Péter Bai, János Hunyadi, István Kertész
Malignant melanoma is the most aggressive form of skin cancer. The early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of this disease. Previous studies have shown that benzamide derivatives (e.g. procainamide) conjugated with PET radionuclides specifically bind to melanin pigment of melanoma tumors. (68)Ga chelating agents can have high influence on physiological properties of (68)Ga labeled bioactive molecules, as was experienced during the application of HBED-CC on PSMA ligand...
March 1, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28273495/-99m-tc-labeling-and-evaluation-of-a-hynic-modified-small-molecular-inhibitor-of-prostate-specific-membrane-antigen
#16
Xiaoping Xu, Jianping Zhang, Silong Hu, Simin He, Xiao Bao, Guang Ma, Jianmin Luo, Jingyi Cheng, Yingjian Zhang
INTRODUCTION: Prostate-specific membrane antigen (PSMA) is a well-established target in the development of radiopharmaceuticals for the diagnosis and therapy of prostate cancer (PCa). In this study, we evaluated a novel (99m)Tc-labeled small molecular inhibitor of PSMA. METHODS: This new small-molecular inhibitor of PSMA, 6-hydrazinonicotinate-Aminocaproic acid-Lysine-Urea-Glutamate (HYNIC-ALUG) was radiolabeled by (99m)Tc and was evaluated both in vitro and in vivo using PCa models (PC-3 and LNCaP)...
January 28, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28272058/psma-targeted-imaging-of-prostate-cancer-evolution-of-a-success-story
#17
Tobias Maurer, Matthias Eiber
No abstract text is available yet for this article.
March 3, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28267455/gallium-68-prostate-specific-membrane-antigen-pet-imaging
#18
REVIEW
Michael S Hofman, Amir Iravani
The role of gallium-68 ((68)Ga) prostate-specific membrane antigen (PSMA) PET imaging is evolving and finding its place in the imaging armamentarium for prostate cancer (PCa). Despite the progress of conventional imaging strategies, significant limitations remain, including identification of small-volume disease and assessment of bone. Clinical studies have demonstrated that (68)Ga-PSMA is a promising tracer for detection of PCa metastases, even in patients with low prostate-specific antigen. To provide an accurate interpretation of (68)Ga-PSMA PET/computed tomography, nuclear medicine specialists and radiologists should be familiar with physiologic (68)Ga-PSMA uptake, common variants, patterns of locoregional and distant spread of PCa, and inherent pitfalls...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267453/imaging-of-prostate-cancer-using-64-cu-labeled-prostate-specific-membrane-antigen-ligand
#19
REVIEW
Aviral Singh, Harshad R Kulkarni, Richard P Baum
Prostate cancer is the most common noncutaneous cancer among men, rendering the diagnosis and staging of significant medical and public interest. One of the most interesting developments in the application of nuclear oncology has been the development of novel diagnostic agents that are able to facilitate targeted therapies using the concept of theranostics. This review summarizes the current and emerging molecular imaging techniques for the investigation of patients with prostate cancer with emphasis on the potential of (64)Cu-PSMA PET/CT in staging, restaging, and the application of theranostics...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28255795/-213-bi-psma-617-targeted-alpha-radionuclide-therapy-in-metastatic-castration-resistant-prostate-cancer
#20
Mike Sathekge, Otto Knoesen, Marian Meckel, Moshe Modiselle, Mariza Vorster, Sebastian Marx
No abstract text is available yet for this article.
March 2, 2017: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"